<DOC>
	<DOCNO>NCT00001931</DOCNO>
	<brief_summary>Patients Parkinson 's disease miss chemical neurotransmitter dopamine . This occur result destructive change area brain responsible make dopamine , basal ganglion . Muscle tremor , rigidity movement , shuffle footstep , droopy posture , mask-like expression face characterize Parkinson 's disease . This study design determine effect new drug , N-9023 . The drug act like dopamine give skin patch ( transdermal ) treatment parkinsonian symptom . The goal study find whether N-9023 useful treating sign symptoms Parkinson 's disease determine best dose N-9023 safe effective .</brief_summary>
	<brief_title>Treatment Parkinson 's Disease With Transdermal Skin Patch</brief_title>
	<detailed_description>The acute safety antiparkinsonian efficacy transdermally deliver N-0923 evaluate patient Parkinson 's disease . This dopamine receptor agonist administer transdermally double-blind condition , rise dose paradigm . Antiparkinsonian activity quantify mean standard rating scale . Possible adverse event assess appropriate clinical laboratory test .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>All patient carry diagnosis Parkinson 's Disease base presence characteristic clinical history neurological finding . Symptom severity range Hoehn &amp; Yahr stage IIIV . Males females age 3076 eligible study . Initial emphasis patient take medication levodopa Parkinson 's disease . No presence history medical condition reasonably expect subject patient unwarranted risk . No patient history significant cardiac ( myocardial infarction within 12 month prior study , dysrhythmia ; QTc interval great 440 msec ) . No patient convulsive , hepatic , renal disorder ( exceed upper limit normal value LFT 's creatinine respectively ) . No patient evidence serious medical illness , history alcohol drug abuse , participate investigational trial within 28 day prior study , pregnant nursing woman anyone practice effective mean birth control .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>Continuous Stimulation</keyword>
	<keyword>Dose Finding</keyword>
	<keyword>Skin Patch</keyword>
</DOC>